Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 139

Results For "NCEs"

2548 News Found

SyntheticGestalt collaborates with Enamine to create AI-based model to facilitate drug discovery
Digitisation | January 11, 2024

SyntheticGestalt collaborates with Enamine to create AI-based model to facilitate drug discovery

SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates


Hikal invests Rs. 500 crore into fine chemicals plant at Panoli
News | January 10, 2024

Hikal invests Rs. 500 crore into fine chemicals plant at Panoli

Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit


Tata 1mg and Vitonnix UK get into an exclusive partnership in India
News | January 10, 2024

Tata 1mg and Vitonnix UK get into an exclusive partnership in India

Launch innovative vitamin sublingual sprays


GSK to acquire Aiolos Bio for US$ 1 billion upfront payment
News | January 10, 2024

GSK to acquire Aiolos Bio for US$ 1 billion upfront payment

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway


Hyderabad to host 66th All India Congress of Obstetrics and Gynaecology 2024
News | January 05, 2024

Hyderabad to host 66th All India Congress of Obstetrics and Gynaecology 2024

The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology


Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
Drug Approval | January 03, 2024

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals


Healthcare Triangle completes US$2 million private placement debt offering
Digitisation | January 03, 2024

Healthcare Triangle completes US$2 million private placement debt offering

The company received gross proceeds of approximately US$1.7 million and net proceeds,


Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
News | January 03, 2024

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes


Inspira Technologies closes on $3.88 million RDO
News | January 02, 2024

Inspira Technologies closes on $3.88 million RDO

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering